PARIS, Aug 3 (Reuters) – French drugmaker Sanofi (SASY.PA) said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio (TBIO.O), as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio.
The boards of both companies had approved the deal, the firm added.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Chief Executive Paul Hudson said.Reporting by Matthias Blamont and Sudip Kar-Gupta; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.
NEW YORK, NY, UNITED STATES — Thailand is set to welcome the global textile and…
TAMPA, FL, UNITED STATES — Smith & Associates Real Estate reaffirmed its commitment to community…
BRISBANE, QUEENSLAND, AUSTRALIA — FlyOnE Pty Ltd, Australia’s leading vertically integrated electric aviation company, has…
SAN ANTONIO, TX, UNITED STATES — Eskin Fundraising Training LLC has announced the launch of…
AED200 million investment at Keturah sets standard for next generation of high-end homes built for…
FIA President Mohammed Ben Sulayem says MOU reflects commitment to deliver practical solutions supporting mobility,…